TABLE II.
Potential predictors of time to publication (univariate analyses)
| Factor | Hazard ratio | p Value |
|---|---|---|
| Conference | ||
| asco vs. ispor | 1.94 | 0.038a |
| ash vs. ispor | 2.03 | 0.072 |
| icer | ||
| Dominant icer | 1.21 | 0.639 |
| icer < US$20,000 | 0.99 | 0.963 |
| icer < US$50,000 | 1.19 | 0.568 |
| icer < US$100,000 | 1.38 | 0.452 |
| Cost–utility analysis | 0.79 | 0.349 |
| Cancer type | ||
| Breast | 1.40 | 0.188 |
| Lung | 0.60 | 0.481 |
| Colorectal | 0.77 | 0.544 |
| Prostate | 0.43 | 0.237 |
| Hematologic | 1.34 | 0.287 |
| Drug therapy | 1.53 | 0.234 |
| Curative intent therapy | 1.63 | 0.705 |
| Country | ||
| United States | 1.57 | 0.077 |
| United Kingdom | 1.09 | 0.818 |
| Canada | 0.46 | 0.096 |
| European (non–United Kingdom) | 1.19 | 0.532 |
| Abstract quality | ||
| Base year mentioned | 1.10 | 0.728 |
| Time horizon mentioned | 1.16 | 0.562 |
| Use of life time horizon | 1.67 | 0.065 |
| Discounting mentioned | 0.94 | 0.806 |
| Perspective mentioned | 0.62 | 0.049a |
| Use of societal perspective | 0.50 | 0.051 |
| Sensitivity analysis mentioned | 1.75 | 0.063 |
| Use of psa | 1.42 | 0.245 |
| Financial conflict of interest | 1.07 | 0.845 |
a
Significant at p < 0.05.
icer = incremental cost-effectiveness ratio; asco = American Society of Clinical Oncology; ash = American Society of Hematology; ispor = International Society for Pharmacoeconomics and Outcomes Research; psa = probabilistic sensitivity analysis.